MeiraGTx Holdings Plc MGTX

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most rec

Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company, announced the publication of peer-reviewed data from a multicenter Phase Ib/II multi-dose, open-label clinical trial evaluating the safety, tolerability, and efficacy of GV101 in patients with moderate to severe chronic Graft versus Host Disease (cGvHD). The data, published in Signal Transduction and Targeted Therapy, a Springer Nature Portfolio journal, provide efficacy and findings from the 60 enrolled pat

MeiraGTx Holdings (NasdaqGS:MGTX) announced two senior leadership appointments, adding executives with extensive global pharmaceutical development and manufacturing experience. The company reported a turnaround in second quarter financial performance, shifting from prior net losses to profitability. Management indicated that these leadership changes and financial results could affect MeiraGTx's pipeline progress and commercialization plans. Consider taking a broader look at related...

MeiraGTx (MGTX) is moving closer to becoming a commercial-stage company, with two potential first-in

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concu

Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a novel capsule formulation of GV101, a proprietary oral ROCK2 inhibitor being developed for Friedreich's ataxia (FA). This new fo

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards under the Company’s 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c

Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reache

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for the treatment of LCA4 LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Me

MeiraGTx Holdings PLC (NASDAQ:MGTX) is one of the best gene therapy stocks to buy in 2026. The stock has gained around 25% year-to-date and soared more than 95% over the past year. Looking ahead, analysts believe the stock could explode more than 100% in the next 12 months as MeiraGTx advances its various therapy programs. […]

MeiraGTx Holdings plc ( NASDAQ:MGTX ) missed earnings with its latest first-quarter results, disappointing...